High Immunoreactivity of DUOX2 Is Associated With Poor Response to Preoperative Chemoradiation Therapy and Worse Prognosis in Rectal Cancers

doi:10.7150/jca.19545

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/31689

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31689

Title:	High Immunoreactivity of DUOX2 Is Associated With Poor Response to Preoperative Chemoradiation Therapy and Worse Prognosis in Rectal Cancers
Authors:	Lin, Shih-Chun Chang, I-Wei Hsieh, Pei-Ling Lin, Ching-Yih Sun, Ding-Ping Sheu, Ming-Jen Yang, Ching-Chieh Lin, Li-Ching He, Hong-Lin Tian, Yu-Feng
Contributors:	I Shou Univ, E DA Hosp, Dept Pathol, Div Clin Pathol I Shou Univ, Sch Med Chi Mei Med Ctr, Dept Med Image Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management Chia Nan Univ Pharm & Sci, Dept Pharm Chi Mei Med Ctr, Dept Surg, Div Gen Surg Chi Mei Med Ctr, Dept Radiat Oncol I Shou Univ, E DA Hosp, Dept Pathol, Div Anat Pathol Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Keywords:	CCRT chemoradiotherapy dual oxidase 2 DUOX2 rectal cancer
Date:	2017
Issue Date:	2018-11-30 15:52:59 (UTC+8)
Publisher:	Ivyspring Int Publ
Abstract:	Purpose: Colorectal cancer is the third most common cancer and also the fourth most common cause of cancer mortality worldwide. For rectal cancer, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by radical proctectomy is gold standard treatment for patients with stage II/III rectal cancer. By data mining a documented database of rectal cancer transcriptome (GSE35452) from Gene Expression Omnibus, National Center of Biotechnology Information, we recognized that DUOX2 was the most significantly up-regulated transcript among those related to cytokine and chemokine mediated signaling pathway (GO: 0019221). Hence, the aim of this study was to assess the DUOX2 expression level and its clinicopathological correlation and prognostic significance in patients of rectal cancer. Materials and Methods: DUOX2 immunostain was performed in 172 rectal adenocarcinomas treated with preoperative CCRT followed by radical proctectomy, which were divided into high-and low-expression subgroups. Furthermore, statistical analyses were examined to correlate the relationship between DUOX2 immunoreactivity and important clinical and pathological characteristics, as well as three survival indices: disease-specific survival (DSS), local recurrence-free survival (LRFS) and metastasis-free survival (MeFS). Results: DUOX2 overexpression was linked to post-CCRT tumor advancement, pre- and post-CCRT nodal metastasis and poor response to CCRT (all P <= 0.021). Furthermore, DUOX2 high expression was significantly associated with inferior DSS, LRFS and MeFS in univariate analysis (P <= 0.0097) and also served as an independent prognosticator indicating shorter DSS and LRFS interval in multivariate analysis (hazard ratio (HR) = 3.413, 95% confidence interval (CI): 1.349-8.633; HR = 4.533, 95% CI: 1.499-13.708, respectively). Conclusion: DUOX2 may play a pivotal role in carcinogenesis, tumor progression and response to neoadjuvant CCRT in rectal cancers, and serve as a novel prognostic biomarker. Additional researches to clarify the molecular and biochemical pathways are essential for developing promising DUOX2-targeted therapies for patients with rectal cancers.
Relation:	Journal of Cancer, v.8, n.14, pp.2756-2764
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles [Dept. of Pharmacy] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1312	View/Open
jca.19545.pdf		1375Kb	Adobe PDF	0	View/Open

Loading...